Recommendations Issued for Palliative RT for Symptomatic Bone Mets
By Elana Gotkine HealthDay Reporter
THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology, evidence-based recommendations are presented for the use of palliative external beam radiation therapy (RT) for symptomatic bone metastases.
Sarah Alcorn, M.D., Ph.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues developed evidence-based recommendations for palliative external beam RT in symptomatic bone metastases. Five key questions regarding palliative RT were addressed.
The authors noted that RT is recommended for managing pain from bone metastases and spine metastases with or without spinal cord or cauda equina compression for palliative RT. Regarding other RT modalities, surgery and postoperative RT are conditionally recommended over RT alone for patients with spine metastases causing spinal cord or cauda equina compression. For spine metastases with spinal cord or cauda equina compression, dexamethasone is recommended. Postoperative RT is recommended for patients with nonspine bone metastases requiring surgery. For symptomatic bone metastases, conventional RT is recommended in 800 cGy in one fraction (800 cGy/1fx), 2,000 cGy/5fx, 2,400 cGy/6fx, or 3,000 cGy/10fx. In patients ineligible for surgery and receiving conventional RT for spinal cord or cauda equina compression, 800 cGy/1fx, 1,600 cGy/2fx, 2,000 cGy/5fx, or 3,000 cGy/10fx are recommended. In selected patients with good performance status without surgery or neurological symptoms/signs with symptomatic bone metastases, stereotactic body RT is conditionally recommended over conventional palliative RT. Whole-person assessment is necessary for determination of an optimal RT approach/regimen.
"The use of conformal radiation and dose escalation for symptomatic bone metastases has moved from the experimental domain toward routine clinical care for many patients," Alcorn said in a statement.
Two authors reported ties to pharmaceutical companies.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Survival Improves With Open Hysterectomy for Cervical Cancer
FRIDAY, June 28, 2024 -- For patients with early-stage cervical cancer, disease-free and overall survival are lower for patients undergoing minimally invasive versus open radical...
Precision-Guided Treatment Improves Outcomes for High-Risk Pediatric Cancer
FRIDAY, June 28, 2024 -- Precision-guided treatment improves outcomes for children with high-risk cancer, according to a study published online June 6 in Nature Medicine. Loretta...
Guidelines Address RT for Management of HPV-Linked Oropharyngeal Cancer
FRIDAY, June 28, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online June 18 in Practical Radiation Oncology...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.